Lanreotide Chemical Properties

Boiling point:

1508.2±65.0 °C(Predicted)

Density 

1.40±0.1 g/cm3(Predicted)

storage temp. 

Keep in dark place,Sealed in dry,Store in freezer, under -20°C

pka

9.90±0.15(Predicted)

Sequence

D-2-Nal-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2

InChIKey

PUDHBTGHUJUUFI-VHAAONQQNA-N

Safety Information

WGK Germany 

3

HS Code 

3504009000

MSDS

• Language:English Provider:SigmaAldrich

Lanreotide Usage And Synthesis

Description

Lanreotide is a synthetic octapeptide analogue of somatostatin with enhanced metabolic stability compared with somatostatin. It binds with high affinity to and stimulates the somatostatin receptors SSTR2 and SSTR5, with relatively greater potency at SSTR2 and very low binding to SSTR1, SSTR3 and SSTR4. It is used to treat acromegaly and neuroendocrine tumors.

Chemical Properties

White to off-white lyophilised powder

Uses

Antineoplas tic.

Side effects

Lanreotide depot was generally well tolerated, as 88% of patients had adverse events, compared with the placebo at 90%. Most adverse events were mild (17%) or moderate (44%) in both lanreotide and placebo groups. The most common adverse event was diarrhea at 26% in the lanreotide group and 9% with placebo. Abdominal pain was recorded in 14% of patients taking lanreotide but only occurred in 2% of patients taking placebo. Cholelithiasis occurred in 10% of patients but only 3% in the placebo group. Hyperglycemia occurred in 5% of lanreotide patients but was not observed in placebo patients.

in vivo

Description

Lanreotide is an octapeptide, an analogue of a naturally occurring hormone, somatostatin.

Background

Lanreotide is a peptide inhibitor of a number of endocrine, neuroendocrine, exocrine and paracrine functions. It shows good affinity for peripheral somatostatin receptors (anterior pituitary and pancreatic). In contrast, its affinity for central receptors is much lower. This profile confers a good specificity of action at the level of growth hormone and digestive hormone secretion. Lanreotide shows a much longer duration of action than natural somatostatin. In addition, its marked selectivity for the secretion of growth hormone, compared to that of insulin, makes it a suitable candidate for the treatment of acromegaly. By inhibiting the synthesis of thyroid stimulating hormone (TSH), lanreotide also normalised thyroid function of patients with thyrotrophin secreting adenomas in 50% (8/16) of the per-protocol population treated for 6 months. There was no significant reduction in the size of the adenoma. Furthermore, the inhibitory action of lanreotide on intestinal exocrine secretion, d

Lanreotide(108736-35-2)Related Product Information

• Cetrorelix acetate
• Lanreotide Acetate
• Calcitonin salmon
• Elcatonin
• Leuprorelin acetate
• Gonadorelin acetate
• Ipamorelin
• Liraglutide
• Cetrorelix acetate
• Glucagon
• Degarelix
• Exenatide acetate
• Goserelin
• Lixisenatide
• Lanreotide
• DOTA-BIM-23014:DOTA-Lanreotide,DOTA-Lanreotide
• LANREOTIDE ACETATE
• yttrium 90-DOTA-lanreotide